SLC2A2 and Insulin resistance: Reducing hepatic gluconeogenesis, insulin resistance, chronic low-grade tissue inflammation, increasing leptin, skeletal muscle InsR, hepatic GLUT2, PEPCK expression, increasing HK and PFK activity, and promoting glucose oxidation and utilization